CT P63 and CT P66 antibody cocktail - Celltrion
Alternative Names: CT-P63 and CT-P66 antibody cocktail - CelltrionLatest Information Update: 02 Aug 2022
At a glance
- Originator Celltrion
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown COVID 2019 infections
Most Recent Events
- 25 Jul 2022 Celltrion withdraws a phase III trial in COVID-2019 infections prior to enrollment (Inhalation) (NCT05224856)
- 04 Feb 2022 Clinical trials in COVID-2019 infections in South Korea (Inhalation)
- 04 Feb 2022 Celltrion plans a phase III trial for COVID-2019 infections in April 2022 (NCT05224856)